Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Christopher Pullion"'
Autor:
Carolina V. Alexander‐Savino, Adam Rumage, Christopher Pullion, Richard Straube, Christopher J. Schaber, Elaine S. Gilmore, Brian Poligone
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 4, Pp 1109-1118 (2024)
Abstract Background HyBryteTM is a photodynamic therapy of topical hypericin that has recently been shown to be safe and efficacious in early stage cutaneous T‐cell lymphoma (CTCL). However, its efficacy, absorption, and effect on heart function pa
Externí odkaz:
https://doaj.org/article/a1abaf9268984d1cb9eb156a1bf08dd9
Autor:
Brian Poligone, Carolina V. Alexander-Savino, Ellen J. Kim, Aaron R. Mangold, Jennifer Desimone, Henry K. Wong, Adam T. Rumage, Oreola Donini, Andrea Haulenbeek, Christopher J. Schaber, Richard Straube, Christopher Pullion, Alain H. Rook
Publikováno v:
Frontiers in Drug Discovery, Vol 3 (2023)
Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma of the skin, where at later stages skin-homing malignant T-cells affect lymph nodes, blood, and visceral organs. Even though early CTCL does not affect survival, it can progress
Externí odkaz:
https://doaj.org/article/bdbb6ac6b01d45d1bb769e22f7ae38c8
Autor:
Ellen J. Kim, Aaron R. Mangold, Jennifer A. DeSimone, Henry K. Wong, Lucia Seminario-Vidal, Joan Guitart, James Appel, Larisa Geskin, Edward Lain, Neil J. Korman, Nathalie Zeitouni, Neda Nikbakht, Kenneth Dawes, Oleg Akilov, Joi Carter, Michi Shinohara, Timothy M. Kuzel, Warren Piette, Neal Bhatia, Amy Musiek, David Pariser, Youn H. Kim, Dirk Elston, Erin Boh, Madeleine Duvic, Auris Huen, Theresa Pacheco, Jeffrey P. Zwerner, Seung Tae Lee, Michael Girardi, Christiane Querfeld, Kimberly Bohjanen, Elise Olsen, Gary S. Wood, Adam Rumage, Oreola Donini, Andrea Haulenbeek, Christopher J. Schaber, Richard Straube, Christopher Pullion, Alain H. Rook, Brian Poligone
Publikováno v:
JAMA dermatology. 158(9)
ImportanceGiven that mycosis fungoides−cutaneous T-cell lymphoma (MF/CTCL) is chronic, there is a need for additional therapies with minimal short- and long-term adverse effects. Topical synthetic hypericin ointment, 0.25%, activated with visible l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::324e52e72fb4252fdfaff9693ac02e54
https://pubmed.ncbi.nlm.nih.gov/35857290
https://pubmed.ncbi.nlm.nih.gov/35857290